Biocon’s net profit nearly triples in Q3
January 21st, 2010 - 6:46 pm ICT by IANSBangalore, Jan 21 (IANS) Biotechnology major Biocon Thursday reported a nearly three-fold increase in consolidated profit for the October-December 2009 period at Rs.81 crore from about Rs.28 crore in the same period in 2008.
However, its EBITDA (Earnings before Interest, Taxes, Depreciation, and Amortization) showed a growth of 19.5 percent to Rs.133.12 crore from Rs.111.44 crore in this period.
Net sales increased by 45 per cent to Rs.635 crore for the quarter ended Dec 31, 2009 against Rs.436 crore in the like period last year.
Releasing the results, Biocon’s chairman and managing director Kiran Mazumdar-Shaw said that the company has delivered strong growth in all business segments and they were confident of maintaining this momentum in the next quarter.
The higher profit was driven by robust sales of statins and immuno-suppressants in developed markets, healthy insulin sales in India and emerging markets, strong growth in branded formulations and returns from research services.
- Biocon net up 33 percent in first quarter - Jul 23, 2010
- Biocon net up 25 percent for fourth quarter - Apr 28, 2011
- Biocon net profit up 20 percent in second quarter - Oct 22, 2010
- Biocon quarterly net profit declines 29 percent - Apr 27, 2012
- Ranbaxy reports Rs.464.6 crore net loss - Nov 09, 2011
- Biocon quarterly net profit up 25 percent - Apr 28, 2011
- Biocon net zooms 224 percent in fourth quarter - Apr 29, 2010
- Dabur India Q2 net profit rises 8.42 percent - Oct 31, 2011
- Bajaj Auto net profit soars 163 percent - May 18, 2011
- Mahindra Satyam's net profit up by six percent - Nov 10, 2011
- Reliance Power's Q1 operating revenues up 300 percent - Aug 11, 2011
- Reliance Comm posts Rs.157 crore Q1 profit - Aug 13, 2011
- Hero Motocorp's Q3 net profit up 43 percent - Jan 19, 2012
- Bharti sees modest rise in net profit (Lead) - Jan 22, 2010
- Bajaj Auto's Q3 net profit zooms 19 percent - Jan 19, 2012
Tags: amortization, biocon, biotechnology, business segments, consolidated profit, crore, depreciation, earnings, emerging markets, immuno, insulin, jan 21, managing director, momentum, net profit, net sales, profit nearly triples, q3, shaw, statins